DrugPatentWatch Database Preview➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing
« Back to Dashboard
Chiauranib is an investigational drug.
There have been 7 clinical trials for Chiauranib. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2019.
The most common disease conditions in clinical trials are Ovarian Neoplasms, Lymphoma, Non-Hodgkin, and Lymphoma. The leading clinical trial sponsors are Chipscreen Biosciences, Ltd. and [disabled in preview].
There is one US patent protecting this investigational drug.
Recent Clinical Trials for Chiauranib
|Chiauranib in Combination With Chidamide in Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma||Chipscreen Biosciences, Ltd.||Phase 1/Phase 2|
|Chidamide in Combination With Chemotherapy in Patients With Ovarian Cancer||Chipscreen Biosciences, Ltd.||Phase 2|
|Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma||Chipscreen Biosciences, Ltd.||Phase 1|
Top disease conditions for Chiauranib
Top clinical trial sponsors for Chiauranib
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|Chiauranib||Start Trial||Naphthamide derivatives as multi-target protein kinase inhibitors and histone deacetylase inhibitors||Shenzhen Chipscreen Biosciences Ltd. (Shenzhen, CN)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|